Loading cancer entity…
Loading cancer entity…
Clinical trials
17 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07667335 | Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 30, 2026 | clinicaltrials |
| NCT04963153 | Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 |
| clinicaltrials |
| NCT02496208 | Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors | active not recruiting | Phase 1 | 152 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2026 | clinicaltrials |
Data updated 6 hours agoSource updated Sep 30, 2026source: clinicaltrials